A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
End of Life, Federal Agency Activity, Health and Wellness, Managed Risk, Memory Care Best Practices and Research
The Food and Drug Administration has announced it plans to take concerted efforts to improve the collection and availability of clinical trial data on...
Memory Care Best Practices and Research, Memory Care Education, Reports
Training in “mindfulness,” which is learning how to focus on the present moment, could help improve the emotional wellbeing of those with early-stage ...
Disabilities, End of Life, Health and Wellness, Managed Risk
Three new National Institutes of Health research awards totaling more than $19 million over five years will address the growing proportion of the U.S....
Hearings, Memory Care Best Practices and Research, Memory Care Education
The Senate Special Committee on Aging ventured outside of Washington, DC to hold a field hearing “”Alzheimer’s Disease: A Big Sky Approach to a Nation...
Active & Engaged Seniors, Ageism, Disabilities, Health and Wellness, Memory Care Best Practices and Research
It was a man named Henry, confined to a wheelchair, slumping and inactive that changed Michael Rossato-Bennett’s life, and in turn the lives of many o...
End of Life, Health and Wellness, Managed Risk
The American College of Cardiology has released a free online self-assessment curriculum designed for specialists and other clinicians caring for olde...
Accreditation group CARF International is asking for input on its proposed new and revised standards for aging services dementia care specialty progra...
Disabilities, Health and Wellness, Medication Management
The National Diabetes Education Foundation has released a new guide to help adults address the emotional impact of diabetes via education and support ...
Federal Agency Activity, Medicare, Medication Management
The Centers for Medicare and Medicaid Services is altering rules designed to prevent it from paying twice for the same prescriptions for seniors who r...
Health and Wellness, Managed Risk
The Joint Commission has released an online educational tool designed to help in reducing infections in long-term care settings such as senior living ...